Alliance Pharma (APH)

Sector:

Pharma and Biotech

Index:

FTSE AIM 50

33.10p
   
  • Change Today:
    -0.60p
  • 52 Week High: 71.80
  • 52 Week Low: 32.90
  • Currency: UK Pounds
  • Shares Issued: 540.40m
  • Volume: 1,864,058
  • Market Cap: £178.87m
  • RiskGrade: 119

Alliance Pharma reports resilient first-half trading

By Josh White

Date: Tuesday 18 Jul 2023

LONDON (ShareCast) - (Sharecast News) - Alliance Pharma reported see-through revenues of £82.4m in a first-half trading update on Tuesday, representing a 1.1% increase year-on-year.
However, at constant exchange rates, revenues decreased 1.7%, including revenue from the recent US acquisition of 'ScarAway' and the US rights to 'Kelo-Cote'.

The AIM-traded firm said that, despite some regulatory challenges causing manufacturing delays in certain smaller products, the Kelo-Cote franchise and 'Nizoral' performed in line with expectations, while 'Amberen' revenues returned to growth in the second quarter.

It reported free cash flow of £10.8m in the first half - a significant increase compared to £5.1m in the same period a year earlier.

Net debt also decreased, by £7.5m to £94.5m at period-end on 30 June.

The board said it expected both net debt and group leverage to decline further in the second half, with group leverage expected to be below 2.0x by year-end.

Alliance Pharma said it remained confident in its outlook, anticipating strong gross margin improvement, substantial EBITDA expansion, and a solid second-half performance.

"I am pleased to be back in the business full time and to be focussed on driving the company's growth through the implementation of our long-term strategy," said chief executive officer Peter Butterfield.

"We are encouraged by the recovery in China and the significant market share gains made by Kelo-Cote, along with the excellent progress of Nizoral.

"Meanwhile our wider portfolio continues to provide a robust platform from which to grow our consumer healthcare brands."

Butterfield said the company's free cash flow was expected to continue to build strongly throughout 2023, which it expected would reduce its net debt and leverage by the end of the year.

"The board's expectation for full year operating performance is unchanged."

At 0939 BST, shares in Alliance Pharma were up 9.33% at 49.8p.

Reporting by Josh White for Sharecast.com.

Email this article to a friend

or share it with one of these popular networks:


Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

Note 2: RiskGrade figures are provided by RiskMetrics.

 

Alliance Pharma Market Data

Currency UK Pounds
Share Price 33.10p
Change Today -0.60p
% Change -1.78 %
52 Week High 71.80
52 Week Low 32.90
Volume 1,864,058
Shares Issued 540.40m
Market Cap £178.87m
RiskGrade 119

Alliance Pharma Star Ratings

Compare performance with the sector and the market.
more star ratings
Key: vs Market vs Sector
Value
93.55% above the market average93.55% above the market average93.55% above the market average93.55% above the market average93.55% above the market average
100.00% above the sector average100.00% above the sector average100.00% above the sector average100.00% above the sector average100.00% above the sector average
Price Trend
75.35% below the market average75.35% below the market average75.35% below the market average75.35% below the market average75.35% below the market average
12.73% below the sector average12.73% below the sector average12.73% below the sector average12.73% below the sector average12.73% below the sector average
Income
33.67% above the market average33.67% above the market average33.67% above the market average33.67% above the market average33.67% above the market average
71.43% above the sector average71.43% above the sector average71.43% above the sector average71.43% above the sector average71.43% above the sector average
Growth
88.91% below the market average88.91% below the market average88.91% below the market average88.91% below the market average88.91% below the market average
88.57% below the sector average88.57% below the sector average88.57% below the sector average88.57% below the sector average88.57% below the sector average

What The Brokers Say

Strong Buy 4
Buy 0
Neutral 3
Sell 0
Strong Sell 0
Total 7
buy
Broker recommendations should not be taken as investment advice, and are provided by the authorised brokers listed on this page.

Alliance Pharma Dividends

  Latest Previous
  Final Interim
Ex-Div 22-Jun-23 22-Dec-22
Paid 18-Jul-23 19-Jan-23
Amount 1.18p 0.59p

Trades for 03-May-2024

Time Volume / Share Price
16:35 83,605 @ 33.10p
16:35 4,891 @ 33.10p
16:35 1,099 @ 33.10p
16:35 1,203 @ 33.10p
16:35 1,817 @ 33.10p

Alliance Pharma Key Personnel

CEO Peter Butterfield
CFO Andrew Franklin
Chair Camillo Pane

Top of Page